Every 8-K that MiNK Therapeutics, Inc. (INKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INKT filings page.
MiNK Therapeutics, Inc. reported second quarter 2026 results and clinical progress for its lead iNKT cell therapy, agenT-797. Cash and cash equivalents were $8.8 million as of June 30, 2026. Net loss for the quarter was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, in the second quarter of 2025. For the first six months of 2026, net loss was $5.9 million, or $1.20 per share, versus $7.0 million, or $1.76 per share, a decrease attributed to expense discipline.
Clinically, MiNK reported initial Day 28 observations from its randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS, with treated patients alive at Day 28, improved oxygenation, infection control, and no major serious adverse events attributed to agenT-797 in these initial patients. The company also launched a paid, per-patient, physician-initiated named-patient access program for agenT-797 in Brazil, which may generate non-promotional revenue while expanding access under regulatory oversight.
MiNK Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. A total of 3,277,906 shares of common stock were present in person or by proxy, representing 65.79% of shares outstanding and establishing a quorum.
Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors for three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
MiNK Therapeutics, Inc. reported first quarter 2026 financial results and highlighted progress advancing its allo-iNKT cell therapy platform. The company initiated a randomized Phase 2 trial of lead candidate agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026.
MiNK ended the quarter with approximately $9.5 million in cash and cash equivalents, down from about $13.4 million as of December 31, 2025. It repaid roughly $5.2 million related to an Agenus convertible note and raised about $3.0 million via its at-the-market sales agreement. Net loss was approximately $2.7 million, or $0.57 per share, versus about $2.8 million, or $0.70 per share, a year earlier.
MiNK Therapeutics reported a net loss of $2.6 million, or $0.56 per share, for Q4 2025, versus $2.5 million, or $0.62 per share, in Q4 2024. For full-year 2025, net loss was $12.5 million, or $2.93 per share, compared with $10.8 million, or $2.86 per share, in 2024.
The company ended 2025 with $13.4 million in cash and subsequently raised an additional $3.0 million via an at-the-market program, supporting operations through 2026. MiNK highlighted non-dilutive funding, advancing Phase 2 programs in ARDS and GVHD, and multiple 2026 clinical and scientific catalysts.
MiNK Therapeutics used this report to clarify market speculation about its cell therapy candidate agenT-797. The company states it is in active discussions with multiple parties about potential combination clinical trials for agenT-797 and about possible strategic minority investments in the company.
MiNK emphasizes that these talks reflect outside interest in its allogeneic iNKT cell platform, including for serious conditions such as critical illness, but also makes clear that it has not entered into any binding agreements for trials or investments. Any such deals remain uncertain and subject to risk, as highlighted in its previously filed risk factor disclosures.
MiNK Therapeutics reported leadership changes in its finance function. Effective March 13, 2026, the board appointed Melissa Orilall, currently Vice President, Global Financial Operations at Agenus Inc., as Principal Financial Officer, and Austin Charette, Senior Director, Financial Reporting and Compliance at Agenus, as Principal Accounting Officer.
Both executives provide services to MiNK through an Amended and Restated Intercompany Services Agreement with Agenus and do not receive compensation directly from MiNK. The company states there were no new or modified arrangements tied to these designations, and neither appointee has disclosable family relationships or related-party transactions with MiNK’s directors or executive officers.
MiNK Therapeutics reported a change in its board of directors. On September 23, 2025, the company’s Board elected Dr. John Holcomb as a Class II director, with his initial term ending at the 2026 annual meeting of stockholders. This adds new expertise to the board without changing its overall structure.
In connection with his election, Dr. Holcomb received a stock option to purchase 4,174 shares of MiNK common stock under the 2021 Equity Incentive Plan and the non-employee director compensation program. The option has a 10-year term, an exercise price set at the closing market price on the grant date, and vests in three equal annual installments as long as he continues to serve. As a non-employee director, he is also eligible for cash and potential additional equity compensation under the same program.
MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K announcing that on 15 July 2025 it entered into an At-Market Issuance Sales Agreement with B. Riley Securities. The agreement allows the company to issue and sell up to $50 million of common stock from time to time on the open market.
The shares will be offered under the company’s effective Form S-3 shelf registration (File No. 333-268143) via a base prospectus (dated 8 Nov 2022) and a new prospectus supplement dated 15 July 2025. Sales will be made at prevailing market prices, with B. Riley acting as the agent for placement; compensation terms were not disclosed in this filing.
Exhibits include: (1) the full Sales Agreement (Ex 1.1); (2) the legal opinion and consent of Latham & Watkins LLP (Ex 5.1 & 23.1); and (3) the cover-page Inline XBRL file (Ex 104).
Key Implications for Investors
- The facility provides flexible, immediate access to capital that can support R&D, clinical trials or general corporate purposes without negotiating separate financing rounds.
- Issuances will be executed “at-the-market,” potentially creating incremental selling pressure and dilution as shares are sold into the market.
- The $50 million capacity should be evaluated relative to MiNK’s market capitalisation; if sizeable, ongoing issuance could materially increase the share count.
MiNK Therapeutics, Inc. (Nasdaq: INKT) filed an 8-K to highlight new clinical evidence supporting its allogeneic invariant natural killer T-cell therapy, agenT-797.
- Landmark peer-reviewed case: Nature’s Oncogene published a complete, durable remission (>2 years) in a patient with metastatic, treatment-refractory testicular cancer after a single agenT-797 infusion plus nivolumab (trial NCT05108623). No CRS or GVHD observed; donor iNKT cells persisted up to six months.
- Phase 2 gastric cancer signals: At the 2025 AACR Immuno-Oncology meeting, MiNK reported immune activation, increased tumor infiltration and early tumour-control signals in second-line gastric cancer patients previously refractory to checkpoint inhibitors; several patients lived >12 months post-treatment.
- Additional case report: A separate Oncogene paper detailed a metastatic gastric cancer patient who achieved a 42 % tumour reduction and >9 months progression-free survival following a single agenT-797 dose with nivolumab.
- Pipeline momentum: The ongoing Phase 2 gastric cancer study (NCT06251973) is actively enrolling, with further read-outs expected “in upcoming months.”
The filing contains forward-looking statements and reminds investors of risk factors detailed in MiNK’s March 31 2025 10-Q.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K summarizing the results of its Annual Meeting of Stockholders held on 18 June 2025. A quorum was achieved with 2,793,022 shares (70.41% of outstanding) present in person or by proxy. Shareholders voted on three routine proposals outlined in the proxy dated 30 April 2025.
Proposal 1 – Election of Class I Directors: Incumbents Jennifer Buell and Ulf Wiinberg were each re-elected to serve until the 2028 meeting. Support levels were strong, with Buell receiving 2,337,073 “For” votes (98.7% of votes cast, excluding non-votes) and Wiinberg receiving 2,312,077 “For” votes (97.7%). Broker non-votes totaled 424,803 shares.
Proposal 2 – Option Exchange: Shareholders approved the company’s option exchange program, designed to allow eligible employees to exchange existing stock options for new options. The measure passed with 2,269,364 “For”, 97,538 “Against,” and 1,317 “Abstain,” while 424,803 broker non-votes were recorded.
Proposal 3 – Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025, receiving 2,773,188 “For” votes (99.1%), 12,846 “Against,” and 6,988 abstentions.
No other matters were brought before the meeting, and there were no disclosures regarding financial performance, strategic transactions, or changes in control. The filing is primarily procedural, confirming continued shareholder support for existing leadership and governance practices.